Although there are encouraging signs, women are still under-represented in science whether in basic scientific research or at higher decision-making levels.
The latest FDA black eye highlights an internal battle inside an agency struggling to balance a commitment to science with an intensely politicized decision-making process.
Similarly in business, if a senior biopharma executive was forced every day to step through even of fraction of the actual complexity of the science associated with every product, it would be overwhelming, and make decision-making all but impossible.